Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
268 stocks worldwide match these filters · market cap, largest first. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | Rare disease | $139.82B | 475.00 EUR | 0.00% | +10.21% |
| VRTX34.SA | Vertex Pharmaceuticals Incorporated | Rare disease | $139.70B | 88.56 BRL | −87.17% | +14.82% |
| VRTX | Vertex Pharmaceuticals Incorporated | Rare disease | $138.63B | $547.29 | −1.51% | +11.60% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| Rare disease |
| $112.52B |
| $549.02 |
| −1.96% |
| +0.13% |
| ARGX | argenx SE | Rare disease | $65.51B | $1,047.10 | −1.09% | +20.05% |
| A1RG34.SA | argenx SE | Rare disease | $63.16B | 209.16 BRL | −1.87% | +14.71% |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | Rare disease | $35.05B | $241.82 | −51.66% | +0.67% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | Rare disease | $32.28B | 204.00 EUR | −49.94% | −19.59% |
| ALNY | Alnylam Pharmaceuticals, Inc. | Rare disease | $32.12B | $239.00 | −51.77% | −17.13% |
| A1LN34.SA | Alnylam Pharmaceuticals, Inc. | Rare disease | $31.78B | 62.25 BRL | −52.98% | −15.31% |
| INSM | Insmed Incorporated | Rare disease | $27.16B | $124.39 | −41.53% | +19.46% |
| ROIV | Roivant Sciences Ltd. | Rare disease | $26.55B | $36.75 | −3.21% | +8.60% |
| JAZZ | Jazz Pharmaceuticals plc | Rare disease | $16.89B | $249.29 | −6.42% | −2.97% |
| ASND | Ascendis Pharma A/S | Rare disease | $16.41B | $250.25 | −11.31% | −1.65% |
| BBIO | BridgeBio Pharma, Inc. | Rare disease | $15.52B | $79.37 | −15.04% | −7.22% |
| CORT | Corcept Therapeutics Incorporated | Rare disease | $12.95B | $119.80 | −5.21% | +27.19% |
| 0JAV.L | Insmed Incorporated | Rare disease | $12.89B | $125.00 | −41.59% | +0.43% |
| BMRN | BioMarin Pharmaceutical Inc. | Rare disease | $12.70B | $65.61 | −7.57% | +5.70% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | Rare disease | $12.57B | 52.70 EUR | −4.44% | +2.53% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | Rare disease | $12.54B | 166.77 BRL | −4.38% | +12.08% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | Rare disease | $12.52B | $89.12 | −6.67% | +3.89% |
| CYTK | Cytokinetics, Incorporated | Rare disease | $11.01B | $79.20 | −10.32% | −0.31% |
| IONS | Ionis Pharmaceuticals, Inc. | Rare disease | $10.56B | $63.36 | −26.95% | +14.58% |
| KYMR | Kymera Therapeutics, Inc. | Rare disease | $10.53B | $125.55 | −3.46% | +18.26% |
| 0JDI.L | Ionis Pharmaceuticals, Inc. | Rare disease | $10.40B | $63.37 | −26.94% | +3.44% |
| ABVX.PA | ABIVAX Société Anonyme | Rare disease | $10.21B | 102.30 EUR | −26.40% | −5.63% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | Rare disease | $9.93B | $66.19 | −1.21% | +0.05% |
| PTGX | Protagonist Therapeutics, Inc. | Rare disease | $9.80B | $151.50 | −5.79% | +10.71% |
| IMVT | Immunovant, Inc. | Rare disease | $9.07B | $43.89 | −3.37% | +12.83% |
| CRNX | Crinetics Pharmaceuticals, Inc. | Rare disease | $9.00B | $84.84 | −0.05% | +1.17% |
| 4151.T | Kyowa Kirin Co., Ltd. | Rare disease | $8.51B | 2,613.00 JPY | −10.27% | −3.33% |
| RYTM | Rhythm Pharmaceuticals, Inc. | Rare disease | $7.78B | $111.87 | −8.45% | +3.54% |
| SRRK | Scholar Rock Holding Corporation | Rare disease | $7.31B | $60.04 | −2.77% | +21.61% |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | Rare disease | $6.98B | $89.35 | −0.81% | +3.26% |
| ORKA | Oruka Therapeutics, Inc. | Rare disease | $6.58B | $99.44 | −13.92% | +9.94% |
| LQDA | Liquidia Corporation | Rare disease | $6.31B | $71.36 | −23.77% | −17.81% |
| TVTX | Travere Therapeutics, Inc. | Rare disease | $6.24B | $67.12 | −0.56% | +20.05% |
| DNTH | Dianthus Therapeutics, Inc. | Rare disease | $6.13B | $110.76 | −6.04% | +9.01% |
| PTCT | PTC Therapeutics, Inc. Common Stock | Rare disease | $6.07B | $72.69 | −20.01% | −3.58% |
| KNSA | Kiniksa Pharmaceuticals International, plc | Rare disease | $6.05B | $78.68 | −5.14% | −0.96% |
| MIRM | Mirum Pharmaceuticals, Inc. | Rare disease | $5.98B | $98.51 | −24.22% | −12.22% |
| GRFS | Grifols, S.A. | Rare disease | $5.38B | $7.90 | −22.78% | −1.25% |
| DYN | Dyne Therapeutics, Inc. | Rare disease | $4.92B | $26.36 | −3.46% | +1.78% |
| EWTX | Edgewise Therapeutics, Inc. | Rare disease | $4.80B | $44.38 | −8.31% | +9.99% |
| MANE | Veradermics, Incorporated | Rare disease | $4.29B | $102.80 | −21.67% | −7.84% |
| AMLX | Amylyx Pharmaceuticals, Inc. | Rare disease | $4.13B | $37.08 | −9.87% | +89.67% |
| CPRX | Catalyst Pharmaceuticals Inc | Rare disease | $3.85B | $31.49 | −3.29% | 0.00% |
| CAMX.ST | Camurus AB (publ) | Rare disease | $3.79B | 615.00 SEK | −18.49% | −1.68% |
| CLDX | Celldex Therapeutics, Inc. | Rare disease | $3.19B | $40.57 | −10.12% | +14.02% |
| IRON | Disc Medicine, Inc. | Rare disease | $3.17B | $82.67 | −16.91% | +10.74% |
| ARQT | Arcutis Biotherapeutics, Inc. | Rare disease | $3.12B | $25.14 | −20.87% | −11.54% |
| 0RD1.L | Camurus AB (publ) | Rare disease | $2.84B | 609.98 SEK | −18.56% | −0.21% |
| VRDN | Viridian Therapeutics, Inc. | Rare disease | $2.75B | $24.26 | −29.25% | +24.35% |
| VERA | Vera Therapeutics, Inc. | Rare disease | $2.65B | $36.82 | −34.31% | +10.50% |
| RARE | Ultragenyx Pharmaceutical Inc. | Rare disease | $2.61B | $26.44 | −33.72% | +1.77% |
| PHVS | Pharvaris N.V. | Rare disease | $2.60B | $37.00 | −2.96% | +9.97% |
| TRVI | Trevi Therapeutics, Inc. | Rare disease | $2.55B | $17.92 | −11.37% | −2.77% |
| NKTR | Nektar Therapeutics | Rare disease | $2.52B | $73.77 | −32.32% | +4.24% |
| BCRX | BioCryst Pharmaceuticals, Inc. | Rare disease | $2.51B | $9.83 | −12.39% | +0.92% |
| 009420.KS | Hanall Biopharma Co., Ltd. | Rare disease | $2.36B | 64,000.00 KRW | −12.33% | +53.48% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.